The Drugs Do Work … Better Than My Right Hand

Last weekend a mother brought 4,000£ ($5,200 U.S.) of medicinal cannabis from Holland into the U.K. for her daughter with severe epilepsy. It was confiscated by customs. Last year medicinal cannabis was partially legalized in the U.K. when a similar incident happened. Doctors can now issue prescriptions.

Johns Hopkins Professors Receive $13.4M Grant to Study Best Approach to Treating RRMS

The Patient-Centered Outcomes Research Institute (PCORI) has awarded $13.4 million to two scientists at Baltimore’s Johns Hopkins University (JHU) to study how best to treat newly diagnosed patients with relapsing-remitting multiple sclerosis (RRMS). The study will be led by Dr. Ellen Mowry, an associate professor of neurology and epidemiology at…

Is Ocrevus Right for Me? So Close, Yet So Far

History has been made because of a major breakthrough for multiple sclerosis sufferers everywhere. Ocrevus (ocrelizumab), by Genentech, has been finally approved by the U.S. Food and Drug Administration. It is the first drug treatment that includes my type of MS, primary progressive. This is what I’ve…

#CMSC16 – MS Patients of African Descent May Fare Better on Alemtuzumab (Lemtrada)

A study, recently presented at the Consortium of Multiple Sclerosis Centers (CMSC) 2016 Annual Meeting in National Harbor, Md., showed MS patients of African decent might better benefit from treatment with alemtuzumab (Lemtrada) compared to subcutaneous interferon beta-1a (Rebif) – with lower rates of relapses evident over five years…

MS Neurologist Argues for Continued Use of Natalizumab as Disease Treatment

In a recent study of more than 1,200 patients with multiple sclerosis (MS), a research team reported that treatment with the drug natalizumab (Tysabri) could lead to a tenfold increase in the levels of blood antibodies associated with a virus causing a rare but severe brain disease known as progressive multifocal…